Welcome to our dedicated page for DURECT SEC filings (Ticker: DRRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Finding the trial data that could shift DURECT’s valuation shouldn’t feel like combing through a lab notebook. Biotech SEC filings are dense—hundreds of pages of clinical results, licensing clauses, and risk factors. DURECT Corporation’s 10-K alone details epigenetic therapy science, cash burn projections, and FDA designations that move the stock.
Stock Titan turns that complexity into clarity. Our AI delivers DURECT SEC filings explained simply—from the DURECT annual report 10-K simplified to every DURECT quarterly earnings report 10-Q filing. Need real-time alerts? We stream DURECT Form 4 insider transactions real-time so you can spot confidence buys or option exercises before the market reacts. Each document arrives with an AI-powered summary, key-metric extractions, and plain-language answers to questions like “What does the latest 8-K say about the AHFIRM trial?”
Here’s what you can unlock:
- Pipeline progress and cash-runway analysis inside 10-Qs—perfect for DURECT earnings report filing analysis
- DURECT insider trading Form 4 transactions mapped against clinical milestones to monitor sentiment
- Instant explanations of any DURECT 8-K material events explained—from FDA feedback to licensing deals
- Compensation metrics in the DURECT proxy statement executive compensation section, tied to trial success hurdles
Whether you’re understanding DURECT SEC documents with AI for the first time or scanning DURECT executive stock transactions Form 4 before earnings, Stock Titan provides complete coverage and professional insight—no PDF diving required.
Durect Corporation filed an S-8 registration post-effective submission listing numerous prior S-8 registration statements and the share authorizations under its employee and director plans. The filing records repeated registrations dating from October 5, 2000 through November 14, 2024, including a recent registration of 2,000,000 shares under the 2000 Stock Plan (post 1-for-10 reverse split) and multiple Employee Stock Purchase Plan registrations.
Durect Corporation (DRRX) filed an S-8 post-effective amendment listing numerous prior S-8 registration statements and documenting serial registrations of Common Stock for employee plans from 2000 through November 14, 2024. The filing explicitly registers specific share amounts under the 1998 Incentive Stock Plan, the 2000 Employee Stock Purchase Plan, the 2000 Stock Plan and the 2000 Directors' Stock Option Plan across multiple dates. The document also notes a 1-for-10 reverse stock split of common stock effected on December 5, 2022.
Durect Corporation (DRRX) filed an S-8 post-effective amendment listing a series of prior S-8 registration statements and updating share counts under employee plans. The filing documents multiple historical registrations under the 2000 Stock Plan and the Employee Stock Purchase Plan, and specifically registers 2,000,000 shares of Common Stock under the 2000 Stock Plan (after a 1-for-10 reverse stock split effected December 5, 2022). The document is administrative, reflecting reserved shares for employee compensation plans rather than operating results.
Durect Corporation filed an S-8 post-effective submission listing numerous prior S-8 registration statements and detailing shares reserved under various employee plans. The filing itemizes historical registrations by date and plan, including registrations for the 1998 Incentive Stock Plan, the 2000 Employee Stock Purchase Plan (as amended), the 2000 Stock Plan (as amended), the 2000 Directors' Stock Option Plan and legacy Southern BioSystems and Southern Research Technologies option plans. The filing notes a 1-for-10 reverse stock split effected December 5, 2022, and is signed by CFO Timothy M. Papp.
Durect Corporation filed an S-8 post-effective submission listing multiple prior S-8 registration statements covering employee equity plans and employee stock purchase plans, with specific historical filings and share amounts from 2000 through November 14, 2024. The filing notes a 1-for-10 reverse stock split of common stock effected December 5, 2022, and is signed by CFO Timothy M. Papp.
Durect Corporation (DRRX) submitted an S-8 post-effective amendment registering employee equity under multiple prior S-8 filings. The filing lists numerous prior S-8 registration statements and specifies shares registered under various company plans: Employee Stock Purchase Plan allocations typically of 225,000–350,000 shares in multiple years, large annual allocations to the 2000 Stock Plan (ranging from 2,250,000 to 18,000,000 in certain years), and smaller allocations under Directors' and other option plans. The filing also states a 1-for-10 reverse stock split of common stock effected December 5, 2022.
Durect Corporation (DRRX) submitted a posteffective S-8 registration covering multiple employee plans and lists prior S-8 registrations dating back to 2000. The filing registers shares for several equity plans including the 1998 Incentive Stock Plan, the 2000 Employee Stock Purchase Plan (as amended), the 2000 Stock Plan (as amended) and the 2000 Directors' Stock Option Plan, with specific historical registrations and share amounts noted. The filing also records a 1-for-10 reverse stock split effected on December 5, 2022.
Durect Corporation (DRRX) files an S-8 post-effective amendment listing historical employee equity registrations and a recent reverse stock split. The filing itemizes numerous prior S-8 registrations dating from October 5, 2000 through November 14, 2024 covering employee stock purchase plan shares, stock option plan shares and director option plan shares with amounts ranging from tens of thousands to multi‑million share authorizations (examples: 18,000,000 shares registered on August 5, 2022; 5,500,000 on August 5, 2011). The document also notes a 1‑for‑10 reverse stock split of common stock effected December 5, 2022.
FAQ
What is the current stock price of DURECT (DRRX)?
What is the market cap of DURECT (DRRX)?
